Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

The purpose of this study is to find out the effects of exercise therapy on indicators of prostate cancer in people with low-risk prostate cancer who are on active surveillance. The exercise therapy in this study will be regular home-based walking sessions on a treadmill, and that therapy will be assigned by an exercise physiologist (a medical professional who studies how exercise affects the human body). Some participants in this study will have the assigned exercise therapy, and some participants will participate in their usual exercise routines. Researchers will compare how the assigned exercise therapy and the usual exercise routines affect indicators of prostate cancer in participants. This study will not provide treatment for prostate cancer.

Official Title

Phase 2 Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer

Keywords

Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma, exercise therapy, Memorial Sloan Kettering Cancer Center, 22-419, Prostatic Neoplasms, Adenocarcinoma

Eligibility

You can join if…

Open to males ages 18 years and up

  • Age ≥ 18
  • Men with histologically confirmed localized prostate cancer undergoing active surveillance.
  • Inactive, defined as not meeting the national exercise guidelines for cancer patients (<150 minutes/week of moderate or vigorous exercise)43 as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry (general physical activity screening assessment via smart watch).
  • Screening clearance by an MSK Exercise Physiologist (i.e., review of ECG)
  • BMI <40 kg/m2
  • Cleared for exercise participation as per pre-screening clearance via the Physical Activity Readiness Questionnaire (PAR-Q+) (Appendix B)

You CAN'T join if...

  • Enrollment in any other program that may alter the impact of exercise on tumor outcomes (e.g., weight loss program)
  • Any neoadjuvant anticancer treatment of any kind for prostate cancer in the last 5 years
  • Any history of systemic anticancer therapy in the last 15 years
  • Distant metastatic malignancy of any kind
  • Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation

Locations

  • University of California, Los Angeles (Data and Specimen Analysis Only) not yet accepting patients
    Los Angeles California 90095-1781 United States
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) accepting new patients
    Basking Ridge New Jersey 07920 United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) accepting new patients
    Middletown New Jersey 07748 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Memorial Sloan Kettering Cancer Center
Links
Memorial Sloan Kettering Cancer Center
ID
NCT05751434
Phase
Phase 2 Prostate Cancer Research Study
Study Type
Interventional
Participants
Expecting 102 study participants
Last Updated